IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)	Attorney Docket No. 1761-0013
Zülli et al.	Ś	Theomey 200mer that I was a second
Application No. To be assigned))	Examiner: To be assigned
Filed: Herewith	,))	Group Art Unit: To be assigned
Title: COSMETICS CONTAINING	,)	
ISOFLAVONE AGLYCONES)	

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents Washington, D.C. 20231

"Express mail" mailing label number <u>EV031214227US</u> Date of Deposit <u>February 22, 2002</u> I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents. Box PATENT APPLICATIONS, Washington, D.C. 20231.

Paul J. Ma	nginot	
(Name of per	son mailing	application)

(Signature of person mailing application)

Sir:

Pursuant to 37 CFR §1.56, Applicants hereby disclose the following references, copies of which are enclosed, regarding the above-identified patent application.

Country	Issue Date
Japan	12/27/1983
Japan	08/25/1998
Japan	10/05/1999
Japan	10/31/2000
Europe	01/17/1996
PCT	12/11/1997
PCT	12/17/1998
PCT	07/22/1999
PCT	09/23/1999
Germany	03/21/1996
	Japan Japan Japan Japan Japan Europe PCT PCT PCT PCT



Information Disclosure Statement February 22, 2002

Page 2 of 2

The foregoing references are also listed on the PTO-1449 Form, which is submitted

contemporaneously herewith. A copy of a search report of the European Patent Office

identifying the ten (10) references is also enclosed.

In accordance with 37 C.F.R. § 1.98(a)(3). Applicants' undersigned representative

submits the following concise explanation of the relevance of the non-English language

document cited above and on the accompanying form PTO-1449:

German Patent 44 32 947 A1 discloses isoflavones for treating the skin against

teleangiectatic rosacea, starburst varices, melanomas, alopecia, acne, fatty skin and pigment

spots, as well as hair restorer and radical inhibitor.

It is believed that no fees are due for the consideration of this Information Disclosure

Statement. However, the Commissioner is hereby authorized to charge any deficiency or to

credit any overpayment to Deposit Account No. 13-0014, but not to include any payment of

issue fees.

Respectfully submitted,

MAGINOT, MOORE & BOWMAN

ref mayet

Paul J. Maginot

Attorney for Applicants

Registration No. 34,984

February 22, 2002

Maginot, Moore & Bowman

Bank One Center Tower

111 Monument Circle, Suite 3000

Indianapolis, Indiana 46204-5115

(317) 638-2922 phone

(317) 638-2139 facsimile